Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on November 1, 2018 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO™ (brexanolone) Injection for Treatment of Postpartum Depression
If approved, ZULRESSO would be the first medicine specifically indicated for the treatment of postpartum depression (PPD) CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering
View HTML
Toggle Summary Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss ZULRESSO™ (brexanolone) Injection for the Treatment of Postpartum Depression
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that NASDAQ has halted trading of the company’s common stock.
View HTML
Toggle Summary Sage Therapeutics to Report Third Quarter 2018 Financial Results on Tuesday, November 6, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 23, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 3, 2018-- Sage Therapeutics  (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on October 1, 2018 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Morgan Stanley 16th Annual
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on September 4, 2018 , the Compensation Committee of
View HTML
Toggle Summary Sage Therapeutics Announces The Lancet Publishes Integrated Data from Pivotal Trials for Brexanolone Injection in Postpartum Depression
Results from pivotal trials consistently showed treatment with brexanolone injection provided significant and rapid reduction in depressive symptoms within days of initiating therapy Treatment response was durable over the follow-up period, across three placebo-controlled trials ZULRESSO™
View HTML
Toggle Summary Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
Conditional acceptance granted by U.S. Food and Drug Administration ( FDA ) for the proprietary name ZULRESSO™ for Sage’s intravenous formulation of brexanolone Continuing to execute commercial build and launch readiness for ZULRESSO™ (brexanolone injection) in postpartum depression ahead of PDUFA
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on August 1, 2018 , the Compensation Committee of Sage’s
View HTML